WebTY - JOUR. T1 - Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer WebJan 14, 2024 · RSClin provides individualized estimates of distant relapse risk for women with node-negative, endocrine sensitive, HER2/neu oncogene-negative early breast …
The RSClin tool provides individualized prognosis estimates based …
WebJan 14, 2024 · The RSClin tool integrates genomic and clinical features to determine risk that may guide the decision for adjuvant chemotherapy in node-negative breast cancer … WebExample estimates (solid line) and 95% CIs (dotted lines) provided by the RSClin tool for 10-year distant recurrence risk for endocrine therapy alone with 21-gene expression assay ranging from 0 ... ccsg lending american express
Genomic–transcriptomic evolution in lung cancer and metastasis
WebDOI: 10.1099/mgen.0.000979. Genomic analyses are widely applied to epidemiological, population genetic and experimental studies of pathogenic fungi. A wide range of … WebAug 24, 2024 · On Monday, August 24, 2024, a trademark application was filed for RSCLIN with the United States Patent and Trademark Office. The USPTO has given the RSCLIN trademark a serial number of 90133045. The federal status of this trademark filing is REGISTERED as of Tuesday, March 15, 2024. This trademark is owned by Genomic … WebAug 24, 2024 · Rsclin Application #90133045. Application Filed: 2024-08-24. Trademark Application Details. Mark For: RSCLIN® trademark registration is intended to cover the categories of providing temporary online use of non-downloadable software for use by physicians for ordering patient tests and for use in collecting, managing, analyzing, … ccs global logistics miami